Assessing comorbidity in patients with Parkinson's disease.
The aim of this study was to assess the accuracy of an interview-based assessment of comorbidity, in patients with Parkinson's disease (PD). The Cumulative Illness Rating Scale-Geriatric (CIRS-G) was completed (1) in an interview with 31 PD patients and their caregivers, and (2) by reviewing the patient's medical charts from their general practitioners. Based on the interview, all patients had some comorbidity, 84% had one or more moderate comorbid diseases. The most frequently affected organ systems were "lower gastrointestinal" and "genitourinary". The mean +/- SD total score of the interview-based (chart-based) CIRS-G was 6.9 +/- 3.8 (7.6 +/- 3.5) with a mean of 4.3 +/- 1.9 (5.0 +/- 1.9) affected organ systems and a mean of 2.1 +/- 1.7 (2.3 +/- 1.6) organ systems with at least moderate comorbidity per patient. The agreement (intraclass correlation coefficients) between the interview-based and chart-based assessments for the six summary scores ranged from 0.69 to 0.81. The agreement for the 14 organ systems ranged from 0.13 to 1.00 (weighted kappa); 12 had a K(w) above 0.40 (moderate agreement). The comorbidity summary scores had a moderate correlation with age and disability. The interview-based assessment of the CIRS-G is easy to apply and is an accurate method to assess comorbidity in patients with PD.
Visser
Martine
M
Department of Neurology of the Leiden University Medical Center, Leiden, The Netherlands.
Marinus
Johan
J
Department of Neurology of the Leiden University Medical Center, Leiden, The Netherlands.
van Hilten
Jacobus J
JJ
Department of Neurology of the Leiden University Medical Center, Leiden, The Netherlands.
Schipper
Ruth G B
RGB
Department of Neurology of the Leiden University Medical Center, Leiden, The Netherlands.
Stiggelbout
Anne M
AM
Department of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands.
D000203:Activities of Daily Living; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology; D015897:Comorbidity; D004185:Disability Evaluation; D005767:Gastrointestinal Diseases / Q000453:epidemiology*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D052801:Male Urogenital Diseases / Q000453:epidemiology*; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy / Q000453:epidemiology*; D011320:Primary Health Care / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires
D000978:Antiparkinson Agents; D007980:Levodopa